Methods for screening personal care products

Information

  • Patent Grant
  • 11365397
  • Patent Number
    11,365,397
  • Date Filed
    Wednesday, November 27, 2019
    5 years ago
  • Date Issued
    Tuesday, June 21, 2022
    2 years ago
Abstract
Methods of screening rinse-off personal care compositions can include the use of explant skin in combination with measurements for moisture and/or cell proliferation.
Description
FIELD OF THE INVENTION

The present disclosure generally relates to methods for screening personal care products utilizing skin explants.


BACKGROUND OF THE INVENTION

Over time, cleansing of the skin has become part of a personal hygiene regimen. As this regimen has been more widely adopted, companies and individuals have developed products for cleansing the skin. The skin, however, is a complex organ. At times, products that have been developed to cleanse the skin have been harmful to the skin by overly drying the skin or damaging the skin's barrier properties. While some testing methods have been developed to help screen products and understand their impact to the skin, these methods often rely on in vitro methods which are not truly predictive and/or not consumer relevant. In addition, current in vivo clinical studies are expensive, time consuming, and have a limited throughput. As such, additional screening methods for personal care products are needed.


SUMMARY OF THE INVENTION

As one example, a method of screening a rinse-off personal care composition, comprises: a. selecting a first skin explant from a first culture media; b. applying a control product to the first skin explant; c. adding water and washing the first skin explant with a control product; d. rinsing the control product from the first skin explant with water and drying the first skin explant; e. placing the first skin explant in the first culture media for about 24 hours; f. selecting a second skin explant from a second culture media; g. applying a rinse-off personal care composition to the second skin explant; h. adding water and washing the second skin explant with the rinse-off personal care composition; i. rinsing the rinse-off personal care composition from the second skin explant and drying the second skin explant; j. placing the second skin explant in the second culture media for about 24 hours; k. repeat (b) to (e) for the control product for at least two days; l. repeat (g) to (j) for the rinse-off personal care composition for at least two days; m. compare the condition of the first skin explant and the condition of the second skin explant to assess the efficacy of the control product versus the rinse-off personal care composition.


This and other examples will be more fully described below.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a graph showing an exemplary timeline for evaluation of a personal care composition with a skin explant;



FIG. 2 is a graphic representation of an exemplary daily washing procedure as noted in FIG. 1;



FIG. 3 is a graph showing skin hydration of skin explant treated with water, Personal Care Product (Test A), Personal Care Product (Test B) at days 7 and 14 as measured by a moisture pen;



FIG. 4 is a graph showing MTT skin viability of skin explant treated with water, Personal Care Product (Test A), Personal Care Product (Test B) at days 7 and 14 as measured by an MTT assay;



FIG. 5 is a graph showing Ki67 activity levels in skin explant treated with water, Personal Care Product (Test A), Personal Care Product (Test B) at days 7 and 14 as measured by a Ki67 staining method; and



FIG. 6 is a graph showing TUNEL positive cells in a skin explant treated with water, Personal Care Product (Test A), Personal Care Product (Test B) at days 7 and 14 as measured by a TUNEL assay.





DETAILED DESCRIPTION OF THE INVENTION
Definitions

“Personal care composition” refers to compositions intended for topical application to skin or hair. The personal care compositions can be extrudable or dispensable from a package. Personal care compositions can be in the form of, for example, a liquid, semi-liquid cream, lotion, or gel. Examples of personal care compositions can include but are not limited to shampoo, conditioning shampoo, body wash, moisturizing body wash, shower gels, skin cleansers, cleansing milks, hair and body wash, in shower body moisturizer, pet shampoo, shaving preparations, and cleansing compositions used in conjunction with a disposable cleansing cloth.


“Rinse-off” as used herein refers to a composition which is applied topically to the skin and/or hair and is intended to be subsequently rinsed from the skin and/or hair with water within seconds to a few minutes of application. An example of a product which is rinse-off is a body wash. The product could also be wiped off using a substrate.


Personal care products, like personal cleansers, can help to maintain the skin. Cleansers can help to remove dirt, debris, and other materials from the skin. Cleansers can also impact the skin's moisture, barrier, and other properties. Before a company decides to put a new cleanser on the market, they may want to test the product to understand its impact to the skin or to understand its performance for particular attributes or in certain circumstances.


Testing of this sort can be done in a variety of ways. For example, a cleanser can be placed in a tube and shaken in order to approximate the foam the product will generate during use. When it comes to measuring the impact of a product on the skin, this can be more complicated. Companies can run a clinical study utilizing volunteer subjects, but these tests can be very expensive, can take a long time, and are often limited in the number of products that can be tested at one time. Likewise, tests conducted on skin mimics or artificial skin can give results that are difficult to relate back to real skin or are just not good at predicting the impact on real skin as they can lack the interconnectivity, permeability, and or complexity of human skin.


A beneficial way to test personal care products is with explant skin. Explant skin is skin that has been removed from a person during a medical procedure, like a panniculectomy. The use of actual skin has its advantages. It is less costly than a clinical study, where there is testing on live human subjects, and allows for the screening of more products (i.e. higher throughput). In addition, the results allow for a more in depth understanding of the mechanistic nature of the product's impact on skin.


One downside to the use of explant skin is that it has limited viability. In order to prolong the viability of the skin explant, the explant can be cultured. For example, the explant can be placed into a container with an appropriate culture medium. One example of a suitable culture medium is Dulbecco's Modified Eagle Medium. The culture medium provides nutrients to the skin explant. The culture medium may be iso-osmotic or non-osmotic. The culture medium can include additional additives like an anti-mycotic agent, an antibacterial agent, an amino acid, a vitamin, or a combination thereof. In addition, the subcutaneous layer of the skin explant can be removed to improve absorption of the media into the explant during culturing. An example of explant skin preparation is included in Example 1 below.


As part of the culturing process, a porous membrane may be used. Such membranes are generally placed underneath the skin explant such that the membrane is in the media and the media feeds the skin explant through capillary action through the membrane. It may be desirable to select a membrane that permits the media to pass through it at a particular rate, based on the size and/or type of skin sample. One example of a suitable membrane is the Millipore® brand.


Another mechanism for optimizing the viability of a skin explant is through its storage parameters. These can include for example, time, temperature, humidity, carbon dioxide level, etc. Skin explants can be cultured for example, for about 2 days to about 19 days, about 5 days to about 19 days, about 5 days to about 14 days, about 5 days to about 10 days, or about 6 days to about 8 days. A culturing temperature can be, for example, from 33° C. to 40° C., from 35° C. to 40° C., or even from 36° C. to 38° C. may be suitable, although other temperatures may be acceptable based on the target attribute. Humidity levels for culturing of a skin explant can be, for example, less than 100% humidity, from 40% to 90% humidity, from 50% to 70% humidity, or at a low humidity range of less than 30%, or 20% to 30% humidity. The carbon dioxide level may be, for example, 5%.


In addition, storage parameters can be manipulated to simulate skin conditions. For example, storage conditions can be set to a low humidity, like 20-30%, to simulate winter conditions and/or to generate skin explants which mimic dry skin.


Explant skin can be used to screen for efficacy of personal care compositions. This testing can be done to assess a personal care composition versus a control, like water, or to compare compositions one to the other. Efficacy of a personal care composition could be directed to moisture content of the skin explant. Personal care compositions can impact the moisture content of skin. Change in moisture content of a skin explant can imply the product could have a drying impact on skin (for a decrease in moisture content versus water), a neutral impact (meaning there was relatively no change versus water), or could be moisturizing (for an increase in moisture content versus water). Likewise, where a personal care composition is compared to a second composition, the moisture content of a skin explant can imply differences or similarities in the products with respect to their drying, neutrality, or moisturizing impacts.


Moisture content of a skin explant can be measured in accordance with industry standard testing. Some examples of methods for measuring moisture content of a skin explant include epidermal conductance, epidermal capacitance, bioimpedance, diffusion, and combinations thereof. Epidermal conductance can be measured with a moisture pen. The probe of a moisture pen can be placed on a skin explant where it can measure the level of moisture in the skin and/or give a notification if a skin explant exceeds a preset level of moisture. One example of a moisture pen is manufactured by DermaLab.


Epidermal capacitance can be measured with a corneometer. A corneometer can be used to measure the moisture of a skin explant by placing a probe against the skin explant. The corneometer uses capacitance measurement of a dielectric medium to detect hydration level. One example of a corneometer is Corneometer® CM 825 manufactured by Courage-Khazaka Electronic.


Bioimpedance can be measured utilizing a Skicon instrument. A Skicon instrument can be used to measure the moisture of a skin explant by placing the probe on the skin explant. One example of an acceptable Skicon instrument is the Skicon-200® manufactured by the IBS Company.


Efficacy of a personal care composition can also be assessed by looking at moisture diffusion from a skin explant. Personal care compositions can impact the ability of the skin barrier to retain moisture. The level of moisture loss through the skin explant can imply whether a personal care composition will impact the skin barrier. Level of diffusion of moisture of a skin explant can be measured as transepidermal water loss. If the level of transepidermal water loss is higher than that of a water control or a comparison product then the test product may have a negative impact on skin barrier function, if it is the same or similar, then it has a neutral impact (versus a water control or is similar in efficacy to a comparison product), or if water loss is less than that of a water control or comparison product then then the product may have no impact or less of an impact on barrier function than the control or test products. Transepidermal water loss can be measured with an instrument, like an AquaFlux™ by Nokorode® or with a VapoMeter manufactured by the Delfin Company. Transepidermal water loss is measured by placing a skin explant in a cylinder with two sensors that measure the partial pressure of the water vapor from the skin explant and the gradient between the two sensors is directly proportional to the rate of evaporation.


Efficacy of a personal care composition could also be detected by cell metabolic activity in the skin explant. Personal care compositions can impact the metabolic activity of the cells in the skin explant. The level of metabolic activity in the cells of a skin explant can imply whether a personal care composition will impact the condition of the skin explant. If the level of cell metabolic activity of a test product is higher than that of a water control or a comparison product then the test product is more efficacious (i.e. better for the skin), if it is the same or similar, then it has a neutral impact (versus a water control or is similar in efficacy to a comparison product), or if cell metabolic activity is less than that of a water control or comparison product then the test product is less efficacious (i.e. worse for the skin).


Cell metabolic activity can be assessed by an MTT assay. An MTT assay uses NAD(P)H-dependent cellular oxidoreductase enzymes to reflect the number of viable cells present. These enzymes are capable of reducing the tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to its insoluble formazan, which has a purple color. Rapidly dividing cells exhibit high rates of MTT reduction.


Efficacy of a personal care composition could also be evaluated by measuring the level of a protein related to cell proliferation. One example of such a protein in the Ki67 protein. Personal care compositions can impact the level of the Ki67 protein of the cells in the skin explant. The level of Ki67 protein in the cells of a skin explant can imply whether a personal care composition will impact the underlying health of the skin explant. If the level of Ki67 protein is higher than that of a water control or a comparison product then the test product is better for the underlying condition of the skin explant, if it is the same or similar, then it has a neutral impact (versus a water control or is similar in efficacy to a comparison product), or if Ki67 protein level is less than that of a water control or comparison product then the test product is worse for the underlying condition. The level of Ki67 protein can be measured by a Ki67 staining assay.


Efficacy of a personal care composition can be evaluated by measuring the level of expression of the Natural Moisturization Factor (NMF) biomarkers. NMF biomarkers correlate to a skin explant's ability to maintain its hydration level. Personal care compositions can impact the level of expression NMF biomarkers in the skin explant. The level of NMF biomarker expression in a skin explant can imply whether a personal care composition will impact the ability of the skin to maintain hydration. If the level of NMF biomarker expression is higher than that of a water control or a comparison product then the test product is better at retaining the ability of the skin explant to maintain hydration, if it is the same or similar, then it has a neutral impact (versus a water control or is similar in efficacy to a comparison product), or if the level of expression of NMF biomarkers is less than that of a water control or comparison product then the test product is worse at retaining the ability of the skin to maintain hydration. The level of expression of NMF biomarkers can be measured by standard analytical instruments such as a mass spectrometer.


Efficacy of a personal care composition can also be evaluated by measuring the level of apoptotic DNA fragmentation. One example of a way to measure this is a TUNEL assay. A TUNEL assay can utilize terminal Deoxynucleotidyl transferase tagged with a marker to determine the level of apoptosis. Personal care compositions can impact the level of apoptotic DNA fragmentation in the skin explant. The level of apoptotic DNA fragmentation of a skin explant can imply whether a personal care composition will impact the underlying health of the skin explant. If the level apoptotic DNA fragmentation is higher than that of a water control or a comparison product then the test product is worse for the underlying condition of the skin explant, if it is the same or similar, then it has a neutral impact (versus a water control or is similar in efficacy to a comparison product), or if the level of apoptotic DNA fragmentation is less than that of a water control or comparison product then the test product is better for the underlying condition.


As noted above, explant skin was used to evaluate a rinse-off personal care composition for efficacy. Explant skin was procured and prepared for use. Preparation for use can include, for example, washing and drying, removal of the subcutaneous layer, cutting of the explant skin into appropriately sized pieces, etc. The skin explant was placed in a culture medium. On day 1, prior to product application, a baseline measurement was taken of moisture, MTT skin viability, Ki67 positive cells, and TUNEL positive cells. After the baseline measurement, test product is applied to the skin. In this instance the test products (water, a first personal care composition (Test A), and a second personal care composition (Test B)), are applied to separate pieces of explant skin.


The personal care compositions can be applied as shown in FIG. 2. The explant skin is removed from the media culture and placed in a beaker. 50 μL of a personal care composition is applied to a piece of explant skin in the beaker. The personal care composition is spread on the explant skin using a puff. 1.33 mL of distilled water is then added to the beaker. The puff is then used to wash the epidermis side of the explant skin for 30 seconds. The explant skin is left in the beaker for 90 seconds. The liquid in the beaker with the explant skin is then removed by pouring off the liquid. The explant skin is then rinsed twice, each time with 1 mL of distilled water. The explant skin is removed from the rinse water and tapped dry with sterile cotton. The explant skin is then placed in a container with fresh culture medium. Where the test product is water, it is applied as if it were a personal care composition described above. The test products can be applied once a day for 14 days, as exemplified in FIG. 1, with testing occurring on days 1, 7, and 14.


The moisture of the skin explant for the water control, personal care composition Test A (A) and personal care composition Test B (B) is measured at baseline, day 7, and day 14 as noted in FIGS. 1 and 3. The moisture is measured with a moisture pen. The moisture pen is placed on the surface of the skin explant, where it gives a moisture reading. As can be seen from FIG. 3, personal care compositions Test A and Test B, as well as the water control are measured with a moisture pen. The skin explant on which Personal care composition A was placed had a significantly higher moisture level than both the water control and personal care composition B at both 7 and 14 days. This shows Test A had better skin moisturization than the water control and Test B.


As can be seen in FIG. 4, the skin explants with water control, personal care composition Test A, and personal care composition Test B are tested for MTT skin viability. At day 7, MTT skin viability was higher for personal care composition Test A than both the water control and personal care composition Test B and is higher than personal care composition B at the 14-day time period. This shows Test composition A had better cell viability and skin condition than the water control and composition Test B.


Explant skin contacted with personal care composition Test A, personal care composition Test B, and a water control are also tested at days 7 and 14 for Ki67 viability. At day 7, Ki67 viability was higher for personal care composition A than both the water control and personal care composition B and is higher than personal care composition B at the 14-day time period (see FIG. 5). This shows composition Test A had better Ki67 viability and skin condition than the water control and composition test B.



FIG. 6 shows results of testing of personal care composition Test A, personal care composition Test B, and a water control are also tested at days 7 and 14 for expression of TUNEL in the cells. Personal care composition Test A is similar to that of the water control and less than that of personal care composition Test B at day 7 and is far less than personal care composition Test B at day 15. This shows product A may have similar cell toxicity vs. water control while product B performed worse in cell toxicity vs. water control and product A.


Taken together, Test product A had significantly better performance in skin hydration and impact on underlying skin condition versus the water control and Test product B.


EXAMPLES
Example 1—Skin Explant Preparation

Materials for preparation include: Dulbecco's Modified Eagle Medium plus Glutamax, antibiotic and antimycotics, 1× phosphate buffer solution (PBS (−ca, −mg), 150 mm×15 mm sterile culture dishes, sterile gauze 4×4, disposable safety scalpels, 4 mm disposable biopsy punch, 6-well cell culture inserts, disinfected tweezers, cotton-tipped applicators, 6-well culture plates, ruled, disinfected cutting mat, optionally with a 12×12 ruler, scraper handle, tissue freezing medium, biopsy cassettes, frozen tissue freezing vessels, 10% formalin, shipping containers for fixed tissue, and biohazard/sharps containers.


Skin preparation can involve preparation of media in advance of the arrival of skin (3× media including 500 ml DMEM plus 15 ml of antibiotic and antimycotics; the 3× referred to 3-fold levels of antibiotics/antimycotics used for the initial hour of incubation; 1× Media: 500 ml DMEM plus 5 ml of antibiotic and antimycotics).


On arrival, the skin is removed from the package and soaked in 3×DMEM media and stored at 4° C. for 1 hour. After 1 hour, the skin is removed from the 3×DMEM and rinsed with sterile 1×PBS. The skin is placed in a clean culture dish containing gauze soaked with 1×DMEM. The sample can be put in culture the same day as arrival; though the sample may be stored overnight at 4° C. if desired.


In preparation for culture, the following can be performed on the skin tissue. On a cutting mat, the skin tissue is positioned such that the epidermis is down, and the fat is exposed. The fat is removed with a disposable scalpel by carefully grasping one corner of the skin with sterile serrated forceps and scraping the fat away with the blade held at a 45-degree angle to the skin. After the fat is removed, the surgical edges can be cut off with a scalpel using a scraper as a straight edge guide and to hold the skin in place. Using the scraper as a guide, the skin can be cut into the desired shape and size, such as 1.25 cm wide strips using a ruler (such as the one on optionally provided on the cutting mat) to measure the width. The strip is rinsed in a 100 mm culture dish containing 1×PBS. The strips are cut into 1.25 cm squares and placed in a 100 mm culture dish onto 1×DMEM soaked gauze until they are put into culture 30 minutes later (with time points of 15 minutes, 30 minutes, 45 minutes, or an hour being used in various non-limiting examples).


Example 2

Personal care composition Test A is a commercial body wash called Olay™ Ultra Moisture Body Wash. The key ingredients are: water, petrolatum, sodium trideceth sulfate, sodium chloride, cocamidopropyl betaine, trideceth-3, fragrance, Butyrospermum parkii (shea butter), guar hydroxypropyltrimonium chloride, sodium benzoate, xanthan gum, glyceryl oleate, disodium EDTA, citric acid, sodium hydroxide, acrylates/C10-30 alkyl acrylates cross polymer, etc. This product can be made utilizing standard industry protocol.


Example 3

Personal Care composition Test B is a commercial body wash called Dove™ Deep Moisture. The key ingredients are: water, cocamidopropyl betaine, sodium hydroxypropyl starch phosphate, lauric acid, sodium lauroyl glycinate, sodium lauroyl isethionate, hydrogenated soybean oil, Glycine soja (soybean) oil or Helianthus annus (sunflower) seed oil, sodium chloride, glycerin, fragrance, guar hydropropyltrimonium chloride, DMDM Hydantion, stearic acid, citric acid, BHT, tetrasodium EDTA, etc. This product can be made utilizing standard industry protocol.


The dimensions and values disclosed herein are not to be understood as being strictly limited to the exact numerical values recited. Instead, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as “40 mm” is intended to mean “about 40 mm.”


Every document cited herein, including any cross referenced or related patent or application and any patent application or patent to which this application claims priority or benefit thereof, is hereby incorporated herein by reference in its entirety unless expressly excluded or otherwise limited. The citation of any document is not an admission that it is prior art with respect to any invention disclosed or claimed herein or that it alone, or in any combination with any other reference or references, teaches, suggests or discloses any such invention. Further, to the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall govern.


While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.

Claims
  • 1. A method of screening a rinse-off personal care composition for a dry-skin benefit, comprising: a) selecting a first skin explant from a first culture media, wherein the first skin explant is cultured at a humidity level of 20% to 30% to mimic dry skin;b) applying a control product to the first skin explant;c) adding water and washing the first skin explant with the control product;d) rinsing the control product from the first skin explant with water and drying the first skin explant;e) placing the first skin explant in the first culture media for about 24 hours;f) selecting a second skin explant from a second culture media, wherein the second skin explant is cultured at a humidity level of 20% to 30% to mimic dry skin;g) applying the rinse-off personal care composition to the second skin explant;h) adding water and washing the second skin explant with the rinse-off personal care composition;i) rinsing the rinse-off personal care composition from the second skin explant and drying the second skin explant;j) placing the second skin explant in the second culture media for about 24 hours;k) repeat (b) to (e) for the control product for at least two days;l) repeat (g) to (j) for the rinse-off personal care composition for at least two days;m) compare the condition of the first skin explant and the condition of the second skin explant to assess the efficacy of the control product versus the rinse-off personal care composition.
  • 2. The method of claim 1, wherein the efficacy of the control product versus the rinse-off personal care composition is assessed by moisture content, wherein more moisture content is more efficacious.
  • 3. The method of claim 2, wherein the moisture content is measured via epidermal conductance, epidermal capacitance, bioimpedance, diffusion, or a combination thereof.
  • 4. The method of claim 3, wherein the conductance is measured with a moisture pen.
  • 5. The method of claim 3, wherein the epidermal capacitance is measured by a corneometer.
  • 6. The method of claim 1, wherein the efficacy of the control product versus the rinse-off personal care composition is assessed by cell metabolic activity, wherein more cell metabolic activity is more efficacious.
  • 7. The method of claim 6, wherein cell metabolic activity is assessed by an MTT assay.
  • 8. The method of claim 1, wherein the control product is water.
  • 9. The method of claim 1, wherein the control product is a second personal care composition.
  • 10. The method of claim 1, wherein (k) and (l) are repeated once a day for 3 days to 28 days.
  • 11. The method of claim 1, wherein (k) and (l) are repeated once a day for 5 days to 21 days; once a day for 5 days to 14 days, or once a day for 7 days to 10 days.
US Referenced Citations (484)
Number Name Date Kind
RE3300 McGill Feb 1869 E
RE3315 Merrill Mar 1869 E
2020454 Spaulding Nov 1935 A
2438091 Lynch Mar 1948 A
2528378 Mccabe, Jr. Oct 1950 A
2658072 Kosmin Nov 1953 A
2798053 Brown Jul 1957 A
2986271 Forrer May 1961 A
3455440 West Jul 1969 A
3479429 Morshauser Nov 1969 A
3533955 Pader Oct 1970 A
3542256 Waterman Nov 1970 A
D220248 Blumenthal Mar 1971 S
3618757 Funkhouser Nov 1971 A
3800898 Griffin Apr 1974 A
3850365 Dietrich Nov 1974 A
3852475 Tarangul Dec 1974 A
3899076 Florian Aug 1975 A
3915921 Schlatzer, Jr. Oct 1975 A
3926861 Gerecht Dec 1975 A
3929678 Laughlin et al. Dec 1975 A
3937811 Papantoniou Feb 1976 A
3940351 Schlatzer, Jr. Feb 1976 A
3951679 Bernhard Apr 1976 A
3980767 Chown Sep 1976 A
4062817 Westerman Dec 1977 A
4159028 Barker Jun 1979 A
4263363 Buck Apr 1981 A
4335103 Barker Jun 1982 A
4379753 Bolich, Jr. Apr 1983 A
4384096 Sonnabend May 1983 A
4421902 Chang Dec 1983 A
4425322 Harvey Jan 1984 A
4429097 Chang Jan 1984 A
4514552 Shay Apr 1985 A
4518578 Hayes May 1985 A
4600761 Ruffner Jul 1986 A
4616074 Ruffner Oct 1986 A
D292879 Smith Nov 1987 S
4743698 Ruffner May 1988 A
4772427 Dawson Sep 1988 A
4814160 Carter Mar 1989 A
4879114 Catsimpoolas Nov 1989 A
4966205 Tanaka Oct 1990 A
4980155 Shah Dec 1990 A
5002680 Schmidt Mar 1991 A
5011681 Ciotti Apr 1991 A
5059414 Dallal Oct 1991 A
5104646 Bolich, Jr. Apr 1992 A
5106609 Bolich, Jr. Apr 1992 A
5135748 Ziegler Aug 1992 A
5147576 Montague Sep 1992 A
5223315 Katsura Jun 1993 A
5228912 Herget Jul 1993 A
5292843 Jenkins Mar 1994 A
5294692 Barron Mar 1994 A
5304334 Lahanas Apr 1994 A
5308526 Dias et al. May 1994 A
5342883 Jenkins Aug 1994 A
5364617 Bush Nov 1994 A
5393450 Shana Feb 1995 A
5412142 Wilkerson, III May 1995 A
5455035 Guerrero Oct 1995 A
5462963 Bush Oct 1995 A
5487168 Geiner Jan 1996 A
5487884 Bissett Jan 1996 A
5523619 Mcallister Jun 1996 A
5540853 Trinh Jul 1996 A
5556628 Derian Sep 1996 A
5578299 Starch Nov 1996 A
5612307 Chambers Mar 1997 A
5632420 Lohrman May 1997 A
5635171 Nadaud Jun 1997 A
5652228 Bissett Jul 1997 A
5661189 Grieveson Aug 1997 A
5681852 Bissett Oct 1997 A
5687779 Andersson Nov 1997 A
5716920 Glenn, Jr Feb 1998 A
5770760 Robinson Jun 1998 A
5816451 Renault Oct 1998 A
5817609 He et al. Oct 1998 A
5851978 Shana Dec 1998 A
5873494 Dallas, Jr. Feb 1999 A
5874495 Robinson Feb 1999 A
5914117 Lavaud Jun 1999 A
5916575 Mcatee Jun 1999 A
5925603 D'Angelo Jul 1999 A
5929019 Puvvada Jul 1999 A
5947335 Milio Sep 1999 A
5952286 Puvvada Sep 1999 A
5954213 Gerhart Sep 1999 A
5965500 Puvvada Oct 1999 A
5965501 Rattinger Oct 1999 A
5965502 Balzer Oct 1999 A
5972361 Fowler Oct 1999 A
6051386 Lerner Apr 2000 A
6068834 Kvalnes May 2000 A
D426158 Underwood Jun 2000 S
6080708 Glenn, Jr. et al. Jun 2000 A
6110883 Petri et al. Aug 2000 A
6150312 Puvvada Nov 2000 A
6150313 Harmalker et al. Nov 2000 A
6165395 Kieras Dec 2000 A
6174845 Rattinger Jan 2001 B1
6176391 Rehkemper Jan 2001 B1
6190648 Kouzu Feb 2001 B1
6194364 Glenn, Jr. Feb 2001 B1
D438460 Hammond Mar 2001 S
D439165 Erckelbout Mar 2001 S
6213166 Thibiant Apr 2001 B1
6217888 Oblong Apr 2001 B1
D441645 Longhurst May 2001 S
6232496 Carr May 2001 B1
6245323 Christie Jun 2001 B1
6245344 Thibiant Jun 2001 B1
6268322 St. Lewis Jul 2001 B1
D446121 Maddy Aug 2001 S
6270446 Abelbeck Aug 2001 B1
D448678 Bakic Oct 2001 S
6306806 St. Lewis Oct 2001 B1
6335312 Coffindaffer Jan 2002 B1
6338855 Albacarys Jan 2002 B1
6340723 Nitta Jan 2002 B1
D455655 Bunce Apr 2002 S
6367519 Thibiant Apr 2002 B2
6383999 Coyle May 2002 B1
6385992 Flore, Jr. May 2002 B1
6394323 Mcclean May 2002 B2
6395691 Tsaur May 2002 B1
6407044 Dixon Jun 2002 B2
6413192 Abelbeck Jul 2002 B2
6419783 Rainey Jul 2002 B1
6426326 Mitra Jul 2002 B1
6429177 Williams Aug 2002 B1
6433061 Marchant Aug 2002 B1
D467807 Bakic Dec 2002 S
6495498 Niemiec Dec 2002 B2
6506391 Biatry Jan 2003 B1
6516838 Thibiant Feb 2003 B2
6517939 Moini Feb 2003 B1
6521216 Glandorf Feb 2003 B1
6523457 Ancona Feb 2003 B1
6534456 Hayward Mar 2003 B2
6534457 Mitra Mar 2003 B2
6534458 Kakizawa Mar 2003 B1
6537527 Kvalnes Mar 2003 B1
6547063 Zaveri Apr 2003 B1
6555509 Abbas et al. Apr 2003 B2
6564978 Safian May 2003 B1
6574985 Fiore, Jr. Jun 2003 B2
6589509 Keller Jul 2003 B2
6635702 Schmucker-castner Oct 2003 B1
6645511 Aronson Nov 2003 B2
6652134 Lloyd Nov 2003 B2
6660251 Buenger et al. Dec 2003 B1
6663855 Frechet Dec 2003 B2
6673371 Brown Jan 2004 B2
6673755 Wei Jan 2004 B2
6673756 Sonnenberg et al. Jan 2004 B2
D486398 Lovell Feb 2004 S
6691394 Mcclean Feb 2004 B1
6695510 Look Feb 2004 B1
6716440 Aronson Apr 2004 B2
6723688 Malik Apr 2004 B1
6727209 Pereira Apr 2004 B2
6752982 Colwell et al. Jun 2004 B2
6759376 Zhang Jul 2004 B2
6780826 Zhang Aug 2004 B2
6849584 Geary Feb 2005 B2
D502400 Cinquino Mar 2005 S
D505079 Mulder May 2005 S
6897253 Schmucker-castner May 2005 B2
6916791 Holick et al. Jul 2005 B2
6919303 Pham Jul 2005 B2
6924256 Massaro Aug 2005 B2
D525872 Haubert Aug 2006 S
D525873 Haubert Aug 2006 S
7084104 Martin Aug 2006 B2
7098180 Ganopolsky Aug 2006 B2
D527637 Bakic Sep 2006 S
D528005 Bakic Sep 2006 S
D529388 Bakic Oct 2006 S
D529810 Davies Oct 2006 S
7119059 Librizzi Oct 2006 B2
D533784 Bakic Dec 2006 S
7143893 Kelly Dec 2006 B2
7144542 Holzer Dec 2006 B2
7157414 Librizzi Jan 2007 B2
7229486 Wiersema Jun 2007 B2
7229778 Hendrix Jun 2007 B2
7268104 Krzysik Sep 2007 B2
7273837 Boutique Sep 2007 B2
7288616 Tamareselvy Oct 2007 B2
7354926 Lintner Apr 2008 B2
7488707 Frantz Feb 2009 B2
7511003 Focht Mar 2009 B2
7524807 Clapp Apr 2009 B2
7527077 Mccall May 2009 B2
7531497 Midha May 2009 B2
7537819 Hendricks May 2009 B2
D601425 Miller Oct 2009 S
D601648 Cornelio, Jr. Oct 2009 S
D608648 Rhodes Jan 2010 S
7649047 Tamareselvy Jan 2010 B2
7666824 Krzysik et al. Feb 2010 B2
7666825 Wagner Feb 2010 B2
7737104 Hilliard, Jr. Jun 2010 B2
7749951 Hilliard, Jr. Jul 2010 B2
7754666 Walters Jul 2010 B2
7754667 Walters Jul 2010 B2
7761242 Honkonen Jul 2010 B2
7763419 Hendrix Jul 2010 B2
7767389 Hendrix Aug 2010 B2
7771924 Hendrix Aug 2010 B2
7771925 Hendrix Aug 2010 B2
7776346 Oconnor Aug 2010 B2
7803403 Librizzi Sep 2010 B2
7820609 Soffin Oct 2010 B2
7906475 Walters Mar 2011 B2
7954392 Belcher Jun 2011 B2
D641633 Carnduff Jul 2011 S
D644106 Almstead, Jr. Aug 2011 S
8025902 Librizzi Sep 2011 B2
D646170 Carnduff Oct 2011 S
8029772 Frantz Oct 2011 B2
8067517 Yoshinaka Nov 2011 B2
8093192 Liu Jan 2012 B2
8105996 Wei Jan 2012 B2
8124064 Wei Feb 2012 B2
8124573 Focht Feb 2012 B2
8147853 Taylor Apr 2012 B2
8158566 Wei Apr 2012 B2
D660181 Nowacek May 2012 S
D660704 Simmons May 2012 S
D660705 Simmons May 2012 S
8283852 Lee Oct 2012 B2
8309667 Yoshinaka Nov 2012 B2
D674282 Baldridge Jan 2013 S
D674292 Klich Jan 2013 S
8394361 Frantz Mar 2013 B1
8417474 Datta Apr 2013 B2
D683226 Baldridge May 2013 S
8518991 Gunn Aug 2013 B2
8772212 Restrepo et al. Jul 2014 B2
8785397 Bernard Jul 2014 B2
8795679 Einarsson Aug 2014 B2
8840871 Wei Sep 2014 B2
9101551 Stella Aug 2015 B2
9162085 Dihora et al. Oct 2015 B2
9176144 Donovan et al. Nov 2015 B2
9186642 Dihora et al. Nov 2015 B2
9216143 Restrepo et al. Dec 2015 B2
9352289 Beijne et al. May 2016 B2
9671410 Stella Jun 2017 B2
9675530 Focht Jun 2017 B2
9717674 Guskey Aug 2017 B1
9750674 Wei Sep 2017 B2
9808408 Stella Nov 2017 B2
9931282 Restrepo et al. Apr 2018 B2
9943468 Stevenson Apr 2018 B2
10085924 Wei Oct 2018 B2
10588858 Tamarkin Mar 2020 B2
10942107 Wei et al. Mar 2021 B2
10966916 Wei Apr 2021 B2
10987290 Wei et al. Apr 2021 B2
20010006088 Lyle Jul 2001 A1
20020042448 Sorrentino Apr 2002 A1
20020122772 Lukenbach Sep 2002 A1
20020182112 Thorn Dec 2002 A1
20030003069 Carson Jan 2003 A1
20030083210 Goldberg May 2003 A1
20030147842 Restle et al. Aug 2003 A1
20030161852 Miller Aug 2003 A1
20030171230 Shana'a et al. Sep 2003 A1
20030180246 Frantz Sep 2003 A1
20030207988 Tamareselvy Nov 2003 A1
20030232101 Travis Dec 2003 A1
20040009138 Kling Jan 2004 A1
20040028932 Holzer Feb 2004 A1
20040057920 Focht Mar 2004 A1
20040091445 Dykstra May 2004 A1
20040092415 Focht May 2004 A1
20040092425 Boutique May 2004 A1
20040105827 Grimm Jun 2004 A1
20040146475 Peffly Jul 2004 A1
20040158940 Wells Aug 2004 A1
20040180020 Manelski Sep 2004 A1
20040219119 Wei Nov 2004 A1
20040223929 Clapp Nov 2004 A1
20040223939 Clausen Nov 2004 A1
20040223991 Wei Nov 2004 A1
20040223992 Clapp Nov 2004 A1
20040232023 Bansal Nov 2004 A1
20040235693 Wei Nov 2004 A1
20040235702 Hawkins Nov 2004 A1
20040248748 Wei Dec 2004 A1
20040248749 Mitra Dec 2004 A1
20050003975 Browne Jan 2005 A1
20050019299 Librizzi Jan 2005 A1
20050020468 Frantz Jan 2005 A1
20050049172 Lukenbach Mar 2005 A1
20050063930 Carlsson Mar 2005 A1
20050070452 Librizzi Mar 2005 A1
20050075256 Librizzi Apr 2005 A1
20050100570 Wei May 2005 A1
20050129759 Sojka Jun 2005 A1
20050139574 Simone Jun 2005 A1
20050143269 Wei Jun 2005 A1
20050191709 Hendrix Sep 2005 A1
20050192187 Wagner Sep 2005 A1
20050192188 Wagner Sep 2005 A1
20050192189 Wagner Sep 2005 A1
20050221334 Benson Oct 2005 A1
20050238680 Stella Oct 2005 A1
20050249758 Di Nov 2005 A1
20050269372 Smith Dec 2005 A1
20050276768 Wei Dec 2005 A1
20050287088 Guiramand Dec 2005 A1
20060002880 Peffly Jan 2006 A1
20060008438 Velarde Jan 2006 A1
20060039986 Okamoto Feb 2006 A1
20060040834 Hilliard Feb 2006 A1
20060042184 Perkins Mar 2006 A1
20060079417 Wagner Apr 2006 A1
20060079419 Wagner Apr 2006 A1
20060079420 Wagner Apr 2006 A1
20060079421 Wagner Apr 2006 A1
20060094628 Wei May 2006 A1
20060094635 Pereira May 2006 A1
20060182699 Taylor Aug 2006 A1
20060189495 Librizzi Aug 2006 A1
20060193800 Reinhardt et al. Aug 2006 A1
20060210505 Clapp Sep 2006 A1
20060257348 Walters Nov 2006 A1
20060269501 Johnson Nov 2006 A1
20060276357 Smith Dec 2006 A1
20060276768 Miller Dec 2006 A1
20070141001 Clapp Jun 2007 A1
20070155637 Smith, III Jul 2007 A1
20070187274 Dalea Aug 2007 A1
20070196344 Osborne Aug 2007 A1
20070202488 Hendrix Aug 2007 A1
20070202489 Hendrix Aug 2007 A1
20070202490 Hendrix Aug 2007 A1
20070202491 Hendrix Aug 2007 A1
20070224154 Brumbaugh Sep 2007 A1
20070224696 Honkonen Sep 2007 A1
20070248562 Berry Oct 2007 A1
20070259796 Fevola et al. Nov 2007 A1
20070280976 Taylor Dec 2007 A1
20070286832 Clapp Dec 2007 A1
20080039353 Focht Feb 2008 A1
20080045428 Focht Feb 2008 A1
20080045429 Focht Feb 2008 A1
20080095733 Griffin Apr 2008 A1
20080112913 Librizzi May 2008 A1
20080196787 Comstock Aug 2008 A1
20080233061 Gates Sep 2008 A1
20080242573 Wei Oct 2008 A1
20090005449 Gunn Jan 2009 A1
20090005460 Gunn Jan 2009 A1
20090028809 Cetti Jan 2009 A1
20090042765 Gizaw Feb 2009 A1
20090107062 Pedersen Apr 2009 A1
20090148392 SenGupta Jun 2009 A1
20090162443 Anthony Jun 2009 A1
20090209600 Miner Aug 2009 A1
20090220443 Braksmayer Sep 2009 A1
20090227751 Yoshinaka Sep 2009 A1
20090311348 Einarsson Dec 2009 A1
20090324521 Cetti Dec 2009 A1
20100022454 Norskov-lauritsen Jan 2010 A1
20100022455 Chilkoti Jan 2010 A1
20100022456 Christensen Jan 2010 A1
20100022458 Kopke Jan 2010 A1
20100028376 Einarsson Feb 2010 A1
20100040074 Dropps Feb 2010 A1
20100040075 Kalhoff Feb 2010 A1
20100048706 Subramanyam Feb 2010 A1
20100105102 Hanes Apr 2010 A1
20100158830 Wei Jun 2010 A1
20100184847 Shin Jul 2010 A1
20100190675 Cetti Jul 2010 A1
20100209374 Wei Aug 2010 A1
20100216707 Bernard Aug 2010 A1
20100317677 Hassel Dec 2010 A1
20100322878 Stella Dec 2010 A1
20110033842 Moon Feb 2011 A1
20110038830 Bernard Feb 2011 A1
20110045037 Tamarkin Feb 2011 A1
20110045039 Sunkel Feb 2011 A1
20110064688 Jordan Mar 2011 A1
20110071123 Schwartz Mar 2011 A1
20110089196 Cetti Apr 2011 A1
20110091439 Bernard Apr 2011 A1
20110117225 Wei May 2011 A1
20110162668 Coffindaffer Jul 2011 A1
20110165607 Takeda Jul 2011 A1
20110245124 Tsaur et al. Oct 2011 A1
20110245125 Tsaur Oct 2011 A1
20110247954 Wei Oct 2011 A1
20110250141 Wei Oct 2011 A1
20110251872 Wei Oct 2011 A1
20110253157 Wei Oct 2011 A1
20110253158 Wei Oct 2011 A1
20110257020 Stella Oct 2011 A1
20110257030 Stella Oct 2011 A1
20110257071 Miralles Oct 2011 A1
20110262025 Jarrold Oct 2011 A1
20110262570 Finlay Oct 2011 A1
20110268802 Dihora et al. Nov 2011 A1
20110269657 Dihora Nov 2011 A1
20110280822 Griffin Nov 2011 A1
20110281256 Davis Nov 2011 A1
20110281366 Davis Nov 2011 A1
20110305653 Jordan Dec 2011 A1
20120009285 Wei Jan 2012 A1
20120010303 Mujkic Jan 2012 A1
20120035557 Coffindaffer Feb 2012 A1
20120087882 Fevola Apr 2012 A1
20120093753 Fevola Apr 2012 A1
20120128964 Hulse et al. May 2012 A1
20120184448 Stella Jul 2012 A1
20120197016 Laughlin, II Aug 2012 A1
20120258074 Mills Oct 2012 A1
20120258126 Schoeller Oct 2012 A1
20120276175 Dihora et al. Nov 2012 A1
20120276177 Hilliard, Jr. Nov 2012 A1
20120276210 Dihora Nov 2012 A1
20120282309 Dihora Nov 2012 A1
20120283112 Binder Nov 2012 A1
20120316095 Wei Dec 2012 A1
20130115610 Lanzalaco May 2013 A1
20130115648 Lanzalaco May 2013 A1
20130149273 Wei Jun 2013 A1
20130183360 Lips et al. Jul 2013 A1
20130202667 An Aug 2013 A1
20130225468 Corominas Aug 2013 A1
20130253057 Wei Sep 2013 A1
20130280174 Lipic Oct 2013 A1
20130280192 Carter et al. Oct 2013 A1
20130280193 Carter Oct 2013 A1
20130280202 Stella Oct 2013 A1
20130280356 Stella Oct 2013 A1
20130281551 Stella et al. Oct 2013 A1
20130344012 Cohen Dec 2013 A1
20140023606 Scheunemann Jan 2014 A1
20140057997 Chevalier Feb 2014 A1
20140072533 Lanzalaco Mar 2014 A1
20140131395 Chang May 2014 A1
20140197309 Davis Jul 2014 A1
20140219946 Hloucha Aug 2014 A1
20140273055 Kerr et al. Sep 2014 A1
20140335532 Finlay Nov 2014 A1
20140357714 Braksmayer Dec 2014 A1
20150071977 Dihora Mar 2015 A1
20150096582 Stella Apr 2015 A1
20150098920 Stella Apr 2015 A1
20160122806 Amini May 2016 A1
20160128913 Wei May 2016 A1
20160128927 Wei May 2016 A1
20160128930 Stella May 2016 A1
20160129917 Gariepy May 2016 A1
20160215326 Martin et al. Jul 2016 A1
20160310375 Torres Rivera Oct 2016 A1
20170000711 Jansen Jan 2017 A1
20170049673 Wei Feb 2017 A1
20170165155 Glenn, Jr. Jun 2017 A1
20170165164 Zhao Jun 2017 A1
20170174413 Callens et al. Jun 2017 A1
20170228514 Apte Aug 2017 A1
20170333315 Wei Nov 2017 A1
20180055894 Kim Mar 2018 A1
20180110704 Zhao Apr 2018 A1
20180185255 Wei Jul 2018 A1
20180353394 Skubsch Dec 2018 A1
20180360706 Dihora Dec 2018 A1
20190117546 Wei Apr 2019 A1
20190142714 Dihora May 2019 A1
20190242880 Bredif Aug 2019 A1
20200040373 Wei Feb 2020 A1
20200146967 Wei May 2020 A1
20200360251 Wei Nov 2020 A1
20210077372 Wei et al. Mar 2021 A1
Foreign Referenced Citations (42)
Number Date Country
1153468 Jul 1997 CN
110804666 Feb 2020 CN
0078138 May 1983 EP
1005849 Sep 2001 EP
1243321 Sep 2002 EP
0907345 May 2003 EP
1657159 Aug 2007 EP
2505180 Oct 2012 EP
2233036 Jan 1975 FR
2792728 Oct 2000 FR
2924613 Jun 2009 FR
2245585 Aug 1992 GB
S61155311 Jul 1986 JP
H0395110 Apr 1991 JP
H04149112 May 1992 JP
2010235567 Oct 2010 JP
2016183134 Oct 2016 JP
1020110068049 Jun 2011 KR
1020120009774 Feb 2012 KR
20170102857 Sep 2017 KR
9212911 Aug 1992 WO
9410973 May 1994 WO
9526710 Oct 1995 WO
9534280 Dec 1995 WO
9629979 Oct 1996 WO
9717938 May 1997 WO
9827193 Jun 1998 WO
9927904 Jun 1999 WO
9938491 Aug 1999 WO
9946319 Sep 1999 WO
9955303 Nov 1999 WO
0030597 Jun 2000 WO
0067712 Nov 2000 WO
0075240 Dec 2000 WO
0101931 Jan 2001 WO
0155497 Aug 2001 WO
02100358 Dec 2002 WO
2008074624 Jun 2008 WO
2008148672 Dec 2008 WO
2009081368 Jul 2009 WO
2011133538 Oct 2011 WO
2013037121 Mar 2013 WO
Non-Patent Literature Citations (65)
Entry
Fowler, Practical Dermatology, Jul. 2012, pp. 36-40. (Year: 2012).
Fluhr et al, Skin Research and Technology, 1999, vol. 5, pp. 171-178. (Year: 1999).
Maeno etal, Analytical Methods, Jul. 2017, vol. 9, pp. 4851-4857. (Year: 2017).
Becker et al., Detection of Differentially Regulated Genes in Keratinocytes by cDNA Array Hybridization: Hsp27 and Other Novel Players in Response to Artificial Ultraviolet Radiation, Journal of Investigative Dermatology, vol. 116, No. 6, Jun. 2001, pp. 983-988.
Chng et al. Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare. NatureMicrobiology 2016, vol. 1, No. 16106, (Year: 2016), pp. 1-10.
Cocamidopropyl betaine Product Specification, Edition 1, Jun. 2005, p. 1-51.
Conti et al., Seasonal influences on stratum corneum ceramide 1 fatty acids and the influence of topical essential fatty acids, International Journal of Cosmetic Science 18, 1-12 (1996), 12 pgs.
D.J. Burgess, Practical Analysis of Complex Coacervate Systems, Journal of Colloid and Interface Science, vol. 140, No. 1, Nov. 1990, pp. 227-238.
J. Crank, The Mathematics of Diffusion, 2nd Edition, dated May 24, 1975, 4 pages.
Tahitian Escape Exfoliating Body Wash, XPOQ2752393, Database accession No. 1124626, Jun. 2009 (Jun. 2009) 3 Pages.
Michael Starch et al., “New Cosmetic Ingredients Based onMetathesized Soybean Oil”, ip.com Journal, ip.com Inc., West Henrietta, NY, US, Sep. 9, 2010 (Sep. 9, 2010), XP013140234. 11 Pages.
Michael Starch: “New Cosmetic Ingredients Based on Soybean Oil”, ip.com journal, ip.com Inc., West Henrietta NY, US, Jun. 15, 2007, pp. 6, 12, 14.
Milton, Section 9.2: Testing Hypotheses on a Proportion, Introduction to Probability and Statistics, Fourth Edition, Sep. 30, 2002, pp. 129-131.
Mintel Database “Extra Mild Moisturising Bar”, XP0O2752390, Database accession No. 2527423, Sep. 2014 (Sep. 2014, 5 Pages.
Mintel Database “Healthy Shower Gel”, Mar. 2011 (Mar. 2011), XP002752392. Database accession No. 1513292, 3 Pages.
Mintel Database, “Shampoo”, XPO02752391, Database accession No. 2242340, Nov. 2013 (Nov. 2013), 2 Pages.
PCT International Search Report and Written Opinion for PCT/US2019/062605 dated Feb. 21, 2020, 12 pgs.
Product Data Sheet, N000557—Jun. 2009 (Year: 2009), 1 Page.
Rimpro India, Surfactant, 2011, 2 Pages.
Silva et al. Insights into the skin microbiome dynamics of leprosy patients during multi-drug therapy and in healthy individuals fromBrazil. Scientific Reports Jun. 8, 2018, 8:8783, pp. 1-10 (Year: 2018).
Triethanolamine Product Specification, Chemical Book, 2008, pp. 1-3.
Weber et al. Steroid-Free Over-the-Counter Eczema Skin Care Formulations Reduce Risk of Flare, Prolong Time to Flare, andu Reduce Eczema Symptoms in Pediatric Subjects With Atopic Dermatitis Journal of Drugs in Dermatology, 2015, vol. 14, Issue 5, pp. 478-485.
Zeng et al. High-Altitude Living Shapes the Skin Microbiome in Humans and Pigs. Frontiers in Microbiology 2017, vol. 8, article1929, pp. 1-10 (Year: 2017).
“Effects of xerosis and aging on epidermal proliferation and differentiation”, Br. J. Dermatology, 137: pp. 219-225 (1997) M. Engelke.
C. Faller et al. “Predictive ability of reconstructed human epidermis equivalents for the assessment of skin irritation of cosmetics”, Toxicology In Vitro., vol. 16, No. 5, Feb. 22, 2002, pp. 557-572.
Cheng Cheng Zhou et al. Self-Aggregation, Antibacterial Activity, and Mildness of Cyclodextrin/Cationic Trimeric Surfactant Complexes 11, ACS Applied Materials & Interfaces, XP055557529, vol. 8, No. 45, dated Nov. 7, 2016 (Nov. 7, 2016), pp. 30811-30823.
Clariant “Mild Surfactants Clariant Mild Surfactants for Personal Care Applications”, Jul. 23, 2015, 39 Pages.
Draelos. “The effect of Cetaphil Gentle Skin Cleanser on the skin barrier of patients with rosacea”, Cutis Apr. 2006, 77 (4Suppl), 2006, pp. 27-33.
Erhirhie et al. “Medicinal Values of Citrullus lanatus (Watermelon): Pharmacological Review”, International Journal of Research in Pharmaceutical and Biomedical Sciences 2013, vol. 4, No. 4, pp. 1305-1312.
Ertel et al., “Leg wash protocol to assess the skin moisturization potential of personal cleansing products”, International Journal of Cosmetic Science, vol. 21, No. 6 Dec. 1999, pp. 383-397.
FDA CFR 21 201.57 (Apr. 1, 2008 edition), p. 24-39.
Flores et al. “Microbiome of Affected and Unaffected Skin of Patients with Atopic Dermatitis Before and After Emollient Treatment”, Journal of Drugs in Dermatology , 2014, vol. 13, issue 11, pp. 611-618.
Geert De Lathauwer, CD Proceeding 6th World Surfactant Congress CESIO, Berlin Germany, (paper# 154), Jun. 2004, 9 Pages.
Grando et al., “Adrenergic and Cholinergic Control in the Biology of Epidermis: Physiological and Clinical Significance”, Journal of Investigative Dermatology vol. 126, 2006, pp. 1948-1965.
Grice and Segre “The skin microbiome”. Nature Reviews Microbiology 2011, vol. 9, pp. 244-253.
Household Products Database, Brand Information, “Olay Daily Renewal Moisturizing Body Wash, Calming,” [Online] URL: http://householdproducts.nlm.nih.gov/cgi-bin/household/brands?tbl=brands&id=16003084, accessed Feb. 8, 2006, 2 pages.
J. Caelles et al., “Anionic and Cationic Compounds in Mixed Systems”, Cosmetics & Toiletries, vol. 106, Apr. 1991, pp. 49-54.
Jing, G. et al., “Parallel-META 3: Compreshensive taxonomical and functional analysis platform for efficient comparison of microbial communities”, Scientific Reports, 7:40371, DOI: 10.1038/srep40371, 2017, 11 pages.
Joachim W. Fluhrl et al. “Comparative study of five instruments measuring stratum comeum hydration (Comeometer CM 820 and CM 825, Skicon 200, Nova DPM 9003, DermaLab). Part 11. In vivo”, Skin Research and Technology, Jan. 1, 1999, pp. 171-178.
Josias H. Hamman et al. “Composition and Applications of Aloe Vera Leaf Gel”, Published Aug. 8, 2008, Molecules 2008, 13, pp. 1599-1616.
Kikuchi et al., “Improvement of Mild Inflammatory Changes of the Facial Skin Induced by Winter Environment with Daily Applications of a Moisturizing Cream”. A Half-Side Test of Biophysical Skin Parameters, Cytokine Expression Pattern and the Formation of Cornified Envelope, Dermatology, vol. 207, No. 3, 2003, pp. 269-275.
KOBO Brochure, “Treated Pigments”, May 2000, 20 Pages.
Kong et al. “Performing Skin Microbiome Research: A Method to the Madness”, Journal of Investigative Dermatology, 2016, vol. 137, pp. 561-568.
Kong, et al., “Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis”, Genome Research, Published by Cold Spring Harbor Laboratory Press, 2012, vol. 22, pp. 850-859.
Meisel et al. “Skin Microbiome Surveys are strongly influenced by experimental design”, Journal of Investigative Dermatology, 2016, vol. 136, pp. 947-956.
Niemeyer et al. “A systematic literature review of the human skin microbiome as biomarker for dermatological drug development”. British Journal of Clinical Pharmacology 2018, vol. 84, pp. 2178-2193.
Raja K Sivamani et al: “An Epinephrine-Dependent Mechanism for the Control of UV-Induced Pigmentation”, Journal of Investigative Dermatology, vol. 129, No. 3, Aug. 21, 2008, pp. 784-787.
Rogers et al., “Stratum corneum lipids: the effect of ageing and the seasons”, Archives of Dermatological Research, 288, 1996, pp. 765-770.
Russel M. Walters et al., “Cleansing Formulations That Respect Skin Barrier Integrity”, Dermatology Research and Practice, vol. 2012, XP055557527, Jan. 1, 2012, pp. 1-9.
Sam Osseiran et al. “Characterizing stratum corneum structure, barrier function, and chemical content of human skin with coherent Raman scattering imaging” Biomedical Optics Express, vol. 9. No. 12, Nov. 26, 2018, 19 pages.
Schallreuter et al., “The induction of the α-1-adrenoreceptor signal transduction system on human melanocytes”, Experimental Dermatology 1996; vol. 5, Issue 1, pp. 20-23.
Scott Truong: “Design of a Handheld Skin Moisture Measuring Device for Application towards Eczema” Apr. 3, 2009, https://macsphere.mcmaster.ca/bitstream/11375/14416/1/fulltext.pdf, pp. 8, 9, 17 and 18.
Seite et al. “Using a specific cleanser for patients with mild atopic dermatitis: relationship between clinical efficacy and skin microbiota modification”, SKIN The Journal of Cutaneous Medicine 2017, 1, 44, 10.25251/skin.1.supp.43, 3 pages.
Seite et al., “Barrier function and microbiotic dysbiosis in atopic dermatitis”, Clinical, Cosmetic and Investigational Dermatology, vol. 8, 2015, pp. 479-483.
Sun et al., “A Microbiome-Based Index for Assessing Skin Health and Treatment Effects for Atopic Dermatitis in Children”, mSystems, vol. 4, Issue 4, e00293-19, Jul./Aug. 2019, pp. 1-20.
Tate Owen, Roger Pynn, Jennifer S. Martinez, and Alison Butler; “Micelle-to-Vesicle Transition of an Iron-Chelating Microbial Surfactant, Marinobactin E”, Nov. 12, 2005, Langmuir, 21,26, pp. 12109-12114.
Two et al. “The Cutaneous Microbiome and Aspects of Skin Antimicrobial Defense System Resist Acute Treatment with Topical Skin Cleansers”, Journal of Investigative Dermatology 2016, vol. 136, pp. 1950-1954.
Van Oss, C.J., “Coacervation, Complex Coacervation and Flocculation”, Journal of Dispersion Science, vol. 9, 1989, 14 pages.
Vaughan, C. D., “Solubility, Effects in Product, Package, Penetration and Preservation”, Cosmetics and Toiletries, vol. 103, Oct. 1988, 23 Pages.
Voegeli et al., “Efficient and simple quantification of stratum corneum proteins on tape strippings by infrared densitometry”, Skin Research and Technology 2007, 13, pp. 242-251.
www.single-cell.cn/skin search results retrieved Oct. 5, 2019, 1 Page.
Xu et al., “Skin benfits of moisturising body wash formulas for children with atopic dermatitis: A randomised controlled clinical study in China” Australasian Journal of Dermatology, 2019, 6 Pages.
Yogiraj et al. “Carica papaya Linn: An overview”, International Journal of Herbal Medicine 2014, vol. 2, No. 5, pp. 01-08.
“Dove All Day Moisturizing Body Wash” Online URL: http://www.ewg.org/reports/skindeep2/report.php?type=PRODUCT&id=8801874, XP002332778, 6 Pages.
“The validity and practicality of sun-reactive skin types I through VI”. Arch. Dermatology, 1988, 124, pp. 869-871.
Related Publications (1)
Number Date Country
20200172876 A1 Jun 2020 US
Provisional Applications (1)
Number Date Country
62772711 Nov 2018 US